Perspective Therapeutics, Inc. (NYSE:CATX) Shares Sold by Sphera Funds Management LTD.

Sphera Funds Management LTD. cut its position in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 21.9% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 460,247 shares of the company's stock after selling 129,048 shares during the quarter. Sphera Funds Management LTD. owned 0.68% of Perspective Therapeutics worth $1,468,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. Y Intercept Hong Kong Ltd acquired a new stake in Perspective Therapeutics in the 4th quarter valued at about $33,000. Aigen Investment Management LP acquired a new stake in shares of Perspective Therapeutics in the fourth quarter worth $34,000. National Bank of Canada FI raised its stake in shares of Perspective Therapeutics by 549,900.0% in the 4th quarter. National Bank of Canada FI now owns 11,000 shares of the company's stock valued at $35,000 after acquiring an additional 10,998 shares during the period. ProShare Advisors LLC lifted its holdings in shares of Perspective Therapeutics by 49.1% during the 4th quarter. ProShare Advisors LLC now owns 15,225 shares of the company's stock valued at $49,000 after acquiring an additional 5,011 shares in the last quarter. Finally, Vontobel Holding Ltd. purchased a new stake in Perspective Therapeutics during the 4th quarter worth $51,000. Institutional investors and hedge funds own 54.66% of the company's stock.

Perspective Therapeutics Price Performance

CATX traded down $0.31 on Wednesday, hitting $2.53. 429,627 shares of the company's stock were exchanged, compared to its average volume of 1,030,742. The stock has a fifty day moving average of $2.25 and a two-hundred day moving average of $3.52. Perspective Therapeutics, Inc. has a twelve month low of $1.60 and a twelve month high of $16.70.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on CATX shares. Truist Financial lowered their target price on Perspective Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. Royal Bank of Canada dropped their price objective on shares of Perspective Therapeutics from $16.00 to $15.00 and set an "outperform" rating on the stock in a research note on Thursday, March 27th. Scotiabank assumed coverage on shares of Perspective Therapeutics in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $15.00 target price for the company. HC Wainwright reiterated a "buy" rating and issued a $10.00 price objective on shares of Perspective Therapeutics in a report on Monday, March 31st. Finally, Lifesci Capital upgraded Perspective Therapeutics to a "strong-buy" rating in a research note on Thursday, March 6th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Perspective Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $12.50.

Insider Buying and Selling

In other news, CFO Juan Graham purchased 33,333 shares of the stock in a transaction dated Friday, March 28th. The stock was acquired at an average price of $2.25 per share, for a total transaction of $74,999.25. Following the completion of the transaction, the chief financial officer now owns 35,354 shares of the company's stock, valued at approximately $79,546.50. The trade was a 1,649.33% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Johan M. Spoor acquired 22,026 shares of the company's stock in a transaction that occurred on Friday, March 28th. The stock was purchased at an average cost of $2.24 per share, for a total transaction of $49,338.24. Following the acquisition, the chief executive officer now owns 59,383 shares in the company, valued at approximately $133,017.92. This trade represents a 58.96% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 115,696 shares of company stock valued at $256,344. Insiders own 3.72% of the company's stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.